Trimethoprim-sulfamethoxazole-induced Steven Johnson syndrome in an HIV-infected patient
| Autor: | Syed Ahmed Taqi, Lateef Begum Sami, Angadi Rajasab Nilofer, Syed Ahmed Zaki |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Population HIV Infections Desensitization Oral cavity urologic and male genital diseases Gastroenterology Drug Watch trimethoprim-sulfamethoxazole Anti-Infective Agents Internal medicine Hiv infected Trimethoprim Sulfamethoxazole Drug Combination medicine Humans Pharmacology (medical) heterocyclic compounds Adverse effect education Pharmacology education.field_of_study business.industry Sulfamethoxazole Pneumocystis jirovecii Pneumonia Antimicrobial bacterial infections and mycoses HIV infection Trimethoprim female genital diseases and pregnancy complications P. jirovecii pneumonia Steven Johnson syndrome Stevens-Johnson Syndrome Immunology glutathione enzyme business human activities medicine.drug |
| Zdroj: | Indian Journal of Pharmacology |
| ISSN: | 1998-3751 0253-7613 |
| Popis: | Trimethoprim-sulfamethoxazole (TMP/SMX) is a widely prescribed antimicrobial for the management of several uncomplicated infections. It is commonly used for the treatment and prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in the HIV-infected population. The adverse reaction to TMP/SMX is more frequent and severe in HIV-infected patients as compared to the general population. Here, we report a case of Stevens-Johnson syndrome (SJS) secondary to TMP/SMX. The patient had a generalized cutaneous reaction with involvement of the eyes, oral cavity, and genitals. He had elevated hepatic alanine aminotransferase and aspartate aminotransferase enzyme. TMP/SMX therapy was stopped and supportive treatment was started. His condition improved after eight days of stopping TMP/SMX therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|